Mereo BioPharma (MREO) Operating Expenses (2023 - 2026)

Mereo BioPharma (MREO) has 4 years of Operating Expenses data on file, last reported at $8.8 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at $8.8 million, down 21.75% year-over-year; the trailing twelve-month figure through Mar 2026 was $38.3 million (down 21.22% YoY), and the FY2025 annual result was $40.8 million, down 13.91% from the prior year.
• Operating Expenses climbed to $8.8 million in Q1 2026 per MREO's latest filing, from $8.4 million in the prior quarter.
• Over five years, Operating Expenses peaked at $15.3 million in Q4 2024 and troughed at $6.4 million in Q2 2023.
• A 4-year average of $10.2 million and a median of $9.9 million in 2024 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2024 and 2025: Operating Expenses jumped 100.81% in 2024, then plunged 45.07% in 2025.
• A 4-year view of Operating Expenses shows it stood at $8.4 million in 2023, then soared by 81.82% to $15.3 million in 2024, then slumped by 45.07% to $8.4 million in 2025, then increased by 4.48% to $8.8 million in 2026.
• Business Quant data shows MREO's Operating Expenses at $8.8 million in Q1 2026, $8.4 million in Q4 2025, and $10.3 million in Q3 2025.